

Supplementary Table 1. HLA-A in controls and patients

	Controls (n=3886)	Patients (n=72)	P-value controls vs patients	Survivors (n=62)	Non-survivors (n=10)	P-value survivors vs non-survivors
A*01	855 (22.0)	11 (15.3)	0.20	9 (14.5)	2 (20.0)	0.64
A*02	1698 (43.7)	37 (51.4)	0.23	34 (54.8)	3 (30.0)	0.18
A*03	714 (18.4)	20 (27.8)	0.047	15 (24.2)	5 (50.0)	0.13
A*11	440 (11.3)	7 (9.7)	0.85	4 (6.5)	3 (30.0)	0.051
A*23	289 (7.4)	8 (11.1)	0.25	6 (9.7)	2 (10.0)	0.31
A*24	672 (17.3)	7 (9.7)	0.11	6 (9.7)	1 (10.0)	0.99
A*25	109 (2.8)	1 (1.4)	0.72	1 (1.6)	0	0.99
A*26	266 (6.8)	6 (8.3)	0.63	5 (8.1)	1 (10.0)	0.99
A*29	494 (12.7)	8 (11.1)	0.86	8 (12.9)	0	0.59
A*30	381 (9.8)	6 (8.3)	0.84	5 (8.1)	1 (10.0)	0.99
A*31	141 (3.6)	3 (4.2)	0.75	3 (4.8)	0	0.99
A*32	432 (11.1)	1 (1.4)	0.004	1 (1.6)	0	0.99
A*33	326 (8.4)	6 (8.3)	0.99	6 (9.7)	0	0.59
A*34	40 (1.0)	0	0.99	0	0	----
A*36	11 (0.3)	0	0.99	0	0	----
A*43	0	0	----	0	0	----
A*66	59 (1.5)	1 (1.4)	0.99	1 (1.6)	0	0.99
A*68	331 (8.5)	9 (12.5)	0.21	8 (12.9)	1 (10.0)	0.99
A*69	27 (0.7)	0	0.99	0	0	----
A*74	28 (0.7)	0	0.99	0	0	----
A*80	17 (0.4)	0	0.99	0	0	----

Supplementary Table 2. HLA-B in controls and patients

	Controls (n=3886)	Patients (n=72)	P-value controls vs patients	Survivors (n=62)	Non- survivors (n=10)	P-value survivors vs non-survivors
B*07	590 (15.2)	7 (9.7)	0.25	6 (9.7)	1 (10.0)	0.99
B*08	524 (13.5)	9 (12.5)	0.99	8 (12.9)	1 (10.0)	0.99
B*13	95 (2.4)	2 (2.8)	0.70	1 (1.6)	1 (10.0)	0.26
B*14	586 (15.1)	8 (11.1)	0.41	8 (12.9)	0	0.59
B*15	408 (10.5)	6 (8.3)	0.70	6 (9.7)	0	0.59
B*18	400 (10.3)	11 (15.3)	0.17	8 (12.9)	3 (30.0)	0.17
B*27	205 (5.3)	3 (4.2)	0.99	3 (4.8)	0	0.99
B*35	705 (18.1)	16 (22.2)	0.36	13 (21.0)	3 (30.0)	0.68
B*37	98 (2.5)	3 (4.2)	0.43	2 (3.2)	1 (10.0)	0.37
B*38	176 (4.5)	4 (5.6)	0.57	3 (4.8)	1 (10.0)	0.46
B*39	142 (3.7)	7 (9.7)	0.02	6 (9.7)	1 (10.0)	0.99
B*40	345 (8.9)	5 (6.9)	0.83	3 (4.8)	2 (20.0)	0.14
B*41	79 (2.0)	2 (2.8)	0.66	2 (3.2)	0	0.99
B*42	70 (1.8)	1 (1.4)	0.99	0	1 (10.0)	0.14
B*44	919 (23.6)	21 (29.2)	0.27	19 (30.6)	2 (20.0)	0.71
B*45	128 (3.3)	5 (6.9)	0.09	5 (8.1)	0	0.99
B*46	1 (0.0)	0	0.99	0	0	----
B*47	37 (1.0)	1 (1.4)	0.50	1 (1.6)	0	0.99
B*48	7 (0.2)	0	0.99	0	0	----
B*49	252 (6.5)	3 (4.2)	0.63	3 (4.8)	0	0.99
B*50	289 (7.4)	6 (8.3)	0.66	6 (9.7)	0	0.59
B*51	611 (15.7)	10 (13.9)	0.87	8 (12.9)	2 (20.0)	0.62
B*52	84 (2.2)	1 (1.4)	0.99	0	1 (10.0)	0.14
B*53	150 (3.9)	2 (2.8)	0.99	2 (3.2)	0	0.99
B*54	1 (0.0)	0	0.99	0	0	----
B*55	118 (3.0)	0	0.28	0	0	----
B*56	46 (1.2)	0	0.99	0	0	----
B*57	243 (6.3)	2 (2.8)	0.32	2 (3.2)	0	0.99
B*58	162 (4.2)	3 (4.2)	0.99	3 (4.8)	0	0.99
B*59	1 (0.0)	0	0.99	0	0	----
B*67	5 (0.1)	0	0.99	0	0	----
B*73	2 (0.1)	0	0.99	0	0	----
B*78	11 (0.3)	0	0.99	0	0	----
B*81	2 (0.1)	0	0.99	0	0	----
B*82	1 (0.0)	0	0.99	0	0	----
B*83	0	0	----	0	0	----

Supplementary Table 3. HLA-C in controls and patients

	Controls (n=3886)	Patients (n=72)	P-value controls vs patients	Survivors (n=62)	Non-survivors (n=10)	P-value survivors vs non-survivors
C*01	216 (5.6)	4 (5.6)	0.99	2 (3.2)	2 (20.0)	0.09
C*02	451 (11.6)	9 (12.5)	0.85	8 (12.9)	1 (10.0)	0.99
C*03	559 (14.4)	7 (9.7)	0.31	5 (8.1)	2 (20.0)	0.25
C*04	957 (24.6)	17 (23.6)	0.99	15 (24.2)	2 (20.0)	0.99
C*05	601 (15.5)	13 (18.1)	0.51	11 (17.7)	2 (20.0)	0.99
C*06	698 (18.0)	11 (15.3)	0.64	10 (16.1)	1 (10.0)	0.99
C*07	1658 (42.7)	27 (37.5)	0.40	23 (37.1)	4 (40.0)	0.99
C*08	570 (14.7)	7 (9.7)	0.31	7 (11.3)	0	0.58
C*12	499 (12.8)	12 (16.7)	0.37	9 (14.5)	3 (30.0)	0.35
C*14	152 (3.9)	4 (5.6)	0.53	3 (4.8)	1 (10.0)	0.46
C*15	316 (8.1)	2 (2.8)	0.12	2 (3.2)	0	0.99
C*16	467 (12.0)	16 (22.2)	0.02	16 (25.8)	0	0.10
C*17	134 (3.4)	3 (4.2)	0.74	2 (3.2)	1 (10.0)	0.37
C*18	5 (0.1)	0	0.99	0	0	----

Supplementary Table 4. HLA-DRB1 in controls and patients

	Controls (n=3886)	Patients (n=72)	P-value controls vs patients	Survivors (n=62)	Non-survivors (n=10)	P-value survivors vs non-survivors
DRB1*01	809 (20.8)	19 (26.4)	0.24	18 (29.0)	1 (10.0)	0.27
DRB1*03	874 (22.5)	16 (22.2)	0.99	12 (19.4)	4 (40.0)	0.21
DRB1*04	969 (24.9)	13 (18.1)	0.22	12 (19.4)	1 (10.0)	0.68
DRB1*07	1017 (26.2)	20 (27.8)	0.79	17 (27.4)	3 (30.0)	0.99
DRB1*08	239 (6.2)	8 (11.1)	0.09	6 (9.7)	2 (20.0)	0.31
DRB1*09	56 (1.4)	2 (2.8)	0.29	2 (3.2)	0	0.99
DRB1*10	110 (2.8)	2 (2.8)	0.99	2 (3.2)	0	0.99
DRB1*11	795 (20.5)	17 (23.6)	0.56	16 (25.8)	1 (10.0)	0.43
DRB1*12	56 (1.4)	0	0.63	0	0	----
DRB1*13	1291 (33.2)	22 (30.6)	0.71	18 (29.0)	4 (40.0)	0.48
DRB1*14	179 (4.6)	2 (2.8)	0.77	2 (3.2)	0	0.99
DRB1*15	690 (17.8)	12 (16.7)	0.99	10 (16.1)	2 (20.0)	0.67
DRB1*16	221 (5.7)	5 (6.9)	0.61	4 (6.5)	1 (10.0)	0.54

Supplementary Table 5. HLA-DQB1 in control and patients

	Controls (n=3886)	Patients (n=72)	P-value controls vs patients	Survivors (n=62)	Non- survivors (n=10)	P-value survivors vs non-survivors
DQB1*02	1819 (46.8)	32 (44.4)	0.72	27 (43.5)	5 (50.0)	0.74
DQB1*03:01	1168 (30.1)	21 (29.2)	0.99	20 (32.3)	1 (10.0)	0.26
DQB1*03:02	520 (13.4)	10 (13.9)	0.86	9 (14.5)	1 (10.0)	0.99
DQB1*03:03	182 (4.7)	3 (4.2)	0.99	2 (3.2)	1 (10.0)	0.37
DQB1*04	280 (7.2)	7 (9.7)	0.36	4 (6.5)	3 (30.0)	0.051
DQB1*05	1284 (33.0)	28 (38.9)	0.31	25 (40.3)	3 (30.0)	0.73
DQB1*06	1613 (41.5)	25 (34.7)	0.28	21 (33.9)	4 (40.0)	0.73